ZTS — Zoetis Inc.

As of 2026-09-13 the tape and the narrative agree: on 2026-08-06 Zoetis cut FY2026 guidance for the second straight quarter (revenue $9.12–9.32B, organic -3% to -1%; adjusted EPS $6.15–$6.25), and Q2 Key Dermatology revenue fell 16% YoY to $395M with US in-clinic derm share down 5 points sequentially to ~86%. Wall Street reset targets hard through August (TD Cowen $104→$94, Citi $112→$96, BNP $146→$110, Stifel/Piper to $80), and the consensus rating has drifted to Hold. Even the stock's low beta (0.73) has not protected it — the shares are down 8.3% over three months and 36.9% over six months, and management bought back $550M of stock in Q2 at an average $88.59, roughly 21% above the 2026-09-13 price, which reads to the market as capital allocated into a falling knife.

Revenue growth has decelerated from double digits to nothing: YoY quarterly growth ran +11.0% (Q3'24), +4.7% (Q4'24), +1.4% (Q1'25), +4.2% (Q2'25), +0.5% (Q3'25), +3.0% (Q4'25), +1.9% (Q1'26) and then +0.3% (Q2'26), with Q2'26 organic operational growth actually -1%. This is a structural deceleration, not a one-quarter blip — it coincides exactly with the competitive reset in dermatology. Operating margin, which held at 38.5–40.2% through 2024 into mid-2025, has compressed in both 2026 quarters: 38.1% → 36.3% in Q1 and 40.2% → 38.0% in Q2, a ~200bp YoY squeeze consistent with higher gross-to-net promotional spend (gross margin itself held ~72%, so the pressure is landing below the gross line). Diluted EPS has still ground higher — Q2'26 $1.65 vs Q2'25 $1.61, +2.5% — but that is buyback math, not organic earnings power. The genuinely reassuring line is cash: TTM free cash flow of $2,366M is essentially unchanged from $2,283M a year ago and $2,298M two years ago, meaning this is a growth-and-margin problem, not a cash-generation problem. What is not reassuring is the balance sheet behind the buybacks: stockholders' equity fell from $5.40B (Q3'25) to $3.15B (Q2'26) while long-term debt climbed from $7.07B to $9.05B.

Cheap versus its own history, and cheap-to-fair on absolute metrics — but contingent. As of 2026-09-13 the TTM P/E is 12.0x against a 5-year average of 35.8x, and P/S is 3.22x against a 5-year average of 9.59x; that is roughly a two-thirds de-rating. Forward P/E on the FY2026 adjusted EPS midpoint of $6.20 is ~11.8x, and on the FY2027 consensus of $6.253 it is ~11.7x. Trailing free cash flow of $2.37B on a $30.6B market cap is a ~7.7% FCF yield, and EV/EBITDA screens near 9.9x. The 2.69 PEG ratio is meaningless here — it is a collapsed growth denominator, not a signal. The honest framing: this is only 'cheap' if EPS stabilizes near $6.20. It is not a valuation floor if dermatology share loss continues into 2027.

The market is paying ~11.7x forward earnings for a business with flat revenue and two guidance cuts — i.e., it is pricing a permanent haircut to the dermatology franchise rather than a cyclical dip. That makes this event-driven rather than multiple-driven. If the Q3 2026 print (estimated early-to-mid November 2026) shows Key Dermatology and US clinic foot traffic stabilizing, a re-rate toward the mid-teens P/E is worth roughly $85–90 and the consensus EPS estimate survives; if it shows a third cut, the $6.25 FY2027 number gets marked down and 11.7x stops looking cheap. Focus on the Key Dermatology line and gross-to-net commentary, not the headline adjusted EPS beat (Q2 beat by just $0.01).

Bearish downtrend, not yet oversold. As of 2026-09-13, RSI(14) stood at 41.1 — weak but above the 30 oversold threshold — and price sat 3.3% below the SMA20 (~$75.5), 3.4% below the SMA50 (~$75.6) and 28.6% below the SMA200 (~$102.2), with the 52-week range at $71–$150.05 and the stock at $73. There is no basing pattern: every bounce has been sold and the 200-day remains steeply declining. Entry-timing implication: $71 is the line in the sand. A reclaim of the ~$75.6 SMA50 would be the first real evidence of stabilization; an RSI print below 30 into the $71 support would be a more disciplined accumulation zone than buying mid-range here.

• Consumer discretionary pullback: pet-owner spending elasticity is showing up as lower veterinary clinic foot traffic and deferral of non-essential wellness visits, especially among younger Gen Z/Millennial pet parents under cost-of-living pressure.
• Higher-for-longer rates: premium-multiple healthcare growth names have been de-rated across the board, and Zoetis has gone from a ~36x compounder to a ~12x multiple as its growth premium evaporated.
• Intensifying competitive intensity in canine dermatology and osteoarthritis monoclonal antibodies: heavily funded rivals are using rebates, discounting and generic/biosimilar alternatives, forcing Zoetis to expand gross-to-net promotional spending and compress operating margin.
• Livestock cyclicality cutting both ways: Q2'26 livestock rose 11% to $731M with a 23% US surge partly tied to transitory New World screwworm demand — a tailwind that will not repeat mechanically.
• FX and international mix: the International segment is a large share of revenue, so dollar strength/weakness flows straight into reported growth on top of the organic trend.

• Q3 2026 earnings (estimated early-to-mid November 2026) — the single most important read on whether US companion animal demand and dermatology share have stabilized, or whether gross-to-net erosion is deepening; a third guidance cut would be a materially negative catalyst.
• Continued share repurchases — $550M was bought in Q2 at an average $88.59; buying at ~$73 is far more accretive per dollar, and management has signaled it will keep leaning into buybacks as the primary capital-return lever.
• Pipeline: developmental monoclonal antibody Lenivia, targeted for US FDA approval around 2027, is the main visible non-legacy growth driver and a potential re-rating hook if data and timelines hold.
• Livestock momentum carrying into H2 2026 — Q2 +11% overall and +23% in the US, though part of that is transitory screwworm-related demand.
• Any sign of pricing discipline from dermatology competitors — a stabilization in gross-to-net would be the fastest route to margin and multiple recovery.

• Structural dermatology share loss: US in-clinic derm share dropped 5 points sequentially to ~86% in Q2'26 and Key Dermatology revenue fell 16% YoY to $395M — this is the highest-margin franchise in the portfolio and further erosion hits both EPS and the multiple.
• A third consecutive guidance cut: management has already reduced FY2026 guidance twice; another cut would validate the bear case that this is structural decline rather than a temporary competitive air-pocket.
• Buyback-funded balance sheet: debt-to-equity of 2.94x, long-term debt up to $9.05B and book equity down to $3.15B from $5.40B in three quarters. The current ratio is comfortable at 3.08, but flexibility is narrowing and the Q2 buyback at $88.59 was value-destructive in hindsight.
• Continued multiple compression if rates stay higher for longer, which would cap any re-rate even if fundamentals stabilize.
• Livestock strength is partly transitory — the New World screwworm-driven US surge is not a repeatable baseline, so livestock may not keep offsetting companion animal weakness.
• Generic/biosimilar and new-entrant pressure on both Apoquel/Cytopoint and the Librela osteoarthritis monoclonal antibody franchise.

Not a broken business, but not a confirmed bottom either. A 71% gross margin, 21.5% ROIC, 37% operating margin and ~$2.37B of remarkably stable annual free cash flow are real — and at ~11.7x forward EPS with a ~7.7% FCF yield you are paying a no-growth price for a still-dominant franchise. The problem is that the de-rating is largely justified rather than a mispricing: US in-clinic dermatology share fell 5 points in a single quarter and management has guided down twice. For a patient investor with a multi-year horizon the risk/reward is turning genuinely asymmetric; for anyone who needs confirmation before committing capital, the Q3 2026 print in early November is the gate.

I blended two independent approaches. (1) Forward P/E: 14x FY2027 consensus EPS of $6.253 = $87.50 — a mid-teens multiple, well below the 35.8x five-year average but above the current 11.7x, reflecting a wide-moat, 21.5%-ROIC franchise with impaired but not broken growth. (2) FCF yield: TTM free cash flow of $2,366M capitalized at a 6.75% required yield (a premium to the market for the competitive uncertainty, but far tighter than the 7.7% the stock currently offers) gives ~$35.0B of equity value, or ~$83.60 on ~419M shares. Weighting the P/E approach 60% and the FCF approach 40% yields $85.94, rounded to $86 — roughly 18% above the 2026-09-13 price of $73.00 and slightly below the $87.33 sell-side consensus target.